Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions

被引：1
|
作者：
Fang, Xiaosheng [1 ,2 ]
Sun, Zhongling [3 ]
Xu-Monette, Zijun Y. [1 ,4 ]
Young, Ken H. [1 ,4 ]
机构：
[1] Duke Univ, Med Ctr, Dept Pathol, Hematopathol Div, Durham, NC 27710 USA
[2] Shandong First Med Univ, Shandong Prov Hosp, Dept Hematol, Jinan, Shandong, Peoples R China
[3] Peoples Hosp Zhaoyuan City, Dept Neurol, Zhaoyuan, Shandong, Peoples R China
[4] Duke Canc Inst, Durham, NC USA
来源：
ONCOLOGIST | 2021年 / 26卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1002/onco.13605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4 / 6
页数：3
相关论文
共 50 条
  • [21] Targeting the mTOR pathway in idiopathic multicentric Castleman disease
    Stern, Robert M.
    Berliner, Nancy
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10): : 4086 - 4088
  • [22] Increased mTOR activation in idiopathic multicentric Castleman disease
    Arenas, Daniel J.
    Floess, Katherine
    Kobrin, Dale
    Pai, Ruth-Anne Langan
    Srkalovic, Maya B.
    Tamakloe, Mark-Avery
    Rasheed, Rozena
    Ziglar, Jasira
    Khor, Johnson
    Parente, Sophia A. T.
    Pierson, Sheila K.
    Martinez, Daniel
    Wertheim, Gerald B.
    Kambayashi, Taku
    Baur, Joseph
    Teachey, David T.
    Fajgenbaum, David C.
    BLOOD, 2020, 135 (19) : 1673 - 1684
  • [23] Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease
    Fajgenbaum, David C.
    Kurzrock, Razelle
    IMMUNOTHERAPY, 2016, 8 (01) : 17 - 26
  • [24] Alveolar Hemorrhage in Idiopathic Multicentric Castleman's Disease
    Huang, Lingtong
    Zheng, Xia
    Huang, Xiaohan
    Wang, Lijun
    Fang, Xueling
    He, Guojun
    Tang, Meng
    Shi, Huixian
    Cai, Hongliu
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (05) : 613 - 615
  • [25] Adrenalitis and anasarca in idiopathic multicentric Castleman's disease
    Chen, Luke Y. C.
    Skinnider, Brian F.
    Wilson, Don
    Fajgenbaum, David C.
    LANCET, 2021, 397 (10286): : 1749 - 1749
  • [26] Cytokine pathways in the pathogenesis of idiopathic Multicentric Castleman Disease
    Uhlfelder, D.
    Schaefer, H.
    Blanfeld, M.
    Andruszewski, D.
    Schelmbauer, C.
    Gaida, M.
    Waisman, A.
    Mufazalov, I
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 136 - 136
  • [27] How We Manage Idiopathic Multicentric Castleman Disease
    Brandstadter, Joshua D.
    Fajgenbaum, David C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (09) : 564 - 571
  • [28] Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
    Pierson, Sheila K.
    Kanhai, Karan
    Bagg, Adam
    Alapat, Daisy
    Lim, Megan S.
    Lechowicz, Mary Jo
    Srkalovic, Gordan
    Uldrick, Thomas S.
    van Rhee, Frits
    Fajgenbaum, David C.
    BLOOD, 2021, 138
  • [29] Treatment of Idiopathic Castleman Disease
    van Rhee, Frits
    Greenway, Amy
    Stone, Katie
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (01) : 89 - +
  • [30] International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
    van Rhee, Frits
    Voorhees, Peter
    Dispenzieri, Angela
    Fossa, Alexander
    Srkalovic, Gordan
    Ide, Makoto
    Munshi, Nikhil
    Schey, Stephen
    Streetly, Matthew
    Pierson, Sheila K.
    Partridge, Helen L.
    Mukherjee, Sudipto
    Shilling, Dustin
    Stone, Katie
    Greenway, Amy
    Ruth, Jason
    Lechowicz, Mary Jo
    Chandrakasan, Shanmuganathan
    Jayanthan, Raj
    Jaffe, Elaine S.
    Leitch, Heather
    Pemmaraju, Naveen
    Chadburn, Amy
    Lim, Megan S.
    Elenitoba-Johnson, Kojo S.
    Krymskaya, Vera
    Goodman, Aaron
    Hoffmann, Christian
    Zinzani, Pier Luigi
    Ferrero, Simone
    Terriou, Louis
    Sato, Yasuharu
    Simpson, David
    Wong, Raymond
    Rossi, Jean-Francois
    Nasta, Sunita
    Yoshizaki, Kazuyuki
    Kurzrock, Razelle
    Uldrick, Thomas S.
    Casper, Corey
    Oksenhendler, Eric
    Fajgenbaum, David C.
    BLOOD, 2018, 132 (20) : 2115 - 2124
12345